Article Text

Download PDFPDF
Letter
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Twitter @ColleenMcGreg15

  • JW and ME contributed equally.

  • Contributors ME, JW ran experiments. ME, JW, UO, CPT, JS S-YW, J-FC, PK, SD, EB, DE, DS, JL analysed data. ME, JW, CPT, JS, PS, LJ, MT, PK, CM, SD wrote paper. SD, PK, CGM, CPT, JS designed the study.

  • Funding This study was funded by Leona M. and Harry B. Helmsley Charitable Trust (2107–04731), National Institute for Health Research (COV19-RECPLAS).

  • Competing interests JS has received lecture fees from Takeda and from the Falk Foundation.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.